Gammadelta T cells as a predictor of surgical relapse of Crohn's disease
Loading...
Official URL
Full text at PDC
Publication date
2020
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Citation
Andreu-Ballester JC, Catalán-Serra I, Gil-Borrás R, Marqués-García P, García-Ballesteros C, López Chuliá F, Cuéllar C. Gammadelta T cells as a predictor of surgical relapse of Crohn's disease. Clin Res Hepatol Gastroenterol. 2020 Sep;44(4):586-597. doi: 10.1016/j.clinre.2019.11.003. Epub 2019 Dec 18. PMID: 31864955.
Abstract
Background: We recently demonstrated a decrease in the overall lymphocyte population in the peripheral blood of patients with CD compared to healthy controls and this decrease is more evident in γδ T lymphocytes. The percentages of T cell subsets could reflect the risk of surgical relapse in CD patients. The aim of this study is to study the correlation between αβ and γδ T cell subsets in the peripheral blood of patients with CD and the risk for surgery during follow up.
Methods: A prospective study of 102 patients with CD compared with 102 healthy subjects (control group) matched by age and sex was conducted. Lymphocytic populations of CD3+, CD4+, CD8+, CD56+, and αβ and γδ T cell subsets were measured in the peripheral blood of all participants.
Results: We found evidence of a relationship between lower γδ T cell levels and risk of surgical relapse in CD. The lowest subsets observed in CD patients with surgical relapse were CD3 + γδ, CD3 + CD8 + γδ and CD3 + CD56 + γδ T cells. We observed a relationship between a decrease in γδ T cells and the most severe forms of the disease. The lowest levels of CD3 + γδ and CD3 + CD8 + γδ T cells were observed in the fistulizing phenotype.
Conclusions: The deficit of γδ T cells was related with the severity and the risk for surgicalrelapse in CD patients. Patients with CD3 + γδ deficit were more prone to surgery than patientswithout this deficit. These results suggest that γδ T cells could be used as markers of poorprognosis of CD following the diagnosis of the disease.